SELLAS Q2 2026: $138.3M Cash, REGAL Final Analysis Nears, SLS009 Topline Data Expected in Q4
SLS has more than doubled off its 52-week low of $1.39.
Summary
SELLAS reported Q2 2026 results with $138.3 million in cash, is nearing the final analysis of its Phase 3 REGAL trial for GPS in AML, and expects topline data from the Phase 2 SLS009 trial in Q4 2026.
Key Events · Earnings and Guidance · SLS
-
Q2 2026 Financial Results
Net loss of $9.6 million ($0.05/share) on R&D spend of $6.3 million and G&A of $4.4 million, with cash and equivalents of $138.3 million as of June 30, 2026.
-
REGAL Trial Final Analysis Trigger
The Phase 3 REGAL trial of GPS in AML will undergo final efficacy analysis once the pre-specified 80th event occurs, a critical step toward a potential BLA submission.
-
SLS009 Phase 2 Progress
28 patients enrolled in the 80-patient Phase 2 trial of SLS009 in newly diagnosed frontline AML; topline data expected in Q4 2026.
-
SLS009 Pancreatic Cancer Expansion
Preclinical studies show SLS009 efficacy in pancreatic cancer cells resistant to RAS inhibitors; clinical development preparations underway at a top-tier academic institution.
Analysis · SLS · Life Sciences
A robust $138.3 million cash position, disclosed with SELLAS's Q2 2026 financials, extends the runway well beyond the upcoming REGAL trial readout. The pivotal Phase 3 REGAL trial is approaching the pre-specified 80th event, which will trigger the final efficacy analysis — a potential catalyst for a BLA submission. Meanwhile, the Phase 2 SLS009 trial in frontline AML has enrolled 28 patients, with topline data expected in Q4 2026. Preclinical data also support expansion of SLS009 into pancreatic cancer. The net loss widened to $9.6 million from $6.6 million a year ago, driven by increased R&D and G&A spending in preparation for a potential BLA. Bolstered by recent warrant exercises, the cash balance provides a solid foundation through these critical milestones.
At the time of this filing, SLS was trading at $10.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $1.39 to $15.88. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.